-
2023-506235-15-00
5
2024-11-07
Limited-Stage Small-Cell Lung Cancer (LS SCLC)
-
2022-502959-54-00
5
2023-09-26
Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Ep
-
2023-507776-42-00
5
2024-11-14
Non-small cell lung cancer
-
2023-508012-35-00
5
2024-10-02
Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB
-
2023-507684-19-00
5
2024-07-24
FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer
-
2023-508613-17-00
5
2024-05-29
Neoplasms, Head and Neck
-
2023-504923-20-00
5
2024-04-04
Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer
-
2023-503376-24-00
5
2024-03-20
Metastatic non-small cell lung cancer (NSCLC)
-
2023-503224-66-00
5
2023-10-31
Atrial Fibrillation
-
2023-507149-27-00
5
2019-11-04
Chemotherapy-induced Thrombocytopenia in Adult subjects with Non-small
-
2023-506987-15-00
9
2016-11-17
Metastatic Castration-Resistant Prostate Cancer
-
2023-503539-16-00
5
2025-11-11
Non-small Cell Lung Cancer (NSCLC)
-
2023-504753-12-00
5
2024-10-01
Lung Cancer, Non-Small Cell
-
2023-509190-23-00
5
2024-09-03
Atherosclerotic Cardiovascular Disease
Elevated lp(a)
-
2023-506876-28-00
5
2024-08-01
The medical condition we are investigating is type 1 AMI (STEMI and NS
-
2023-506054-20-00
5
2024-06-05
Adenocarcinoma of the biliary tract (intrahepatic or extrahepatic chol
-
2023-508359-38-00
5
2024-06-05
Early-stage Non-squamous Non-small Cell Lung Cancer
-
2023-508630-34-00
5
2024-05-28
Overweight
-
2023-503428-24-00
4
2024-01-19
Neoplasms, Head and Neck
-
2022-502442-27-00
5
2024-01-08
Obesity
-
2023-505023-31-00
5
2023-11-17
Renal cell carcinoma
-
2022-501863-41-00
5
2023-11-13
Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small
-
2022-501419-15-00
5
2023-08-23
Atrial Fibrillation
-
2022-501939-16-00
5
2023-05-09
Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or H